Sionna Therapeutics, Inc.
Developing novel NBD1 stabilizers and CFTR modulators to treat cystic fibrosis.
SION | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 21 HICKORY DRIVE, SUITE 500, 2451 WALTHAM
- Website:
- https://www.sionnatx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Sionna Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing transformative treatments for cystic fibrosis (CF). The company's mission is to normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Its novel approach centers on stabilizing the protein's nucleotide-binding domain 1 (NBD1), which directly targets the defect caused by F508del, the most common CF-causing mutation. Sionna is advancing a pipeline of proprietary small molecule NBD1 stabilizers, such as SION-719, and a portfolio of complementary CFTR modulators designed to work synergistically. The ultimate goal is to restore CFTR function to near-normal levels, revolutionizing the treatment paradigm for patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Sionna Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sionna Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sionna Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
